Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umang Swami

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
The Journal of Urology|February 10, 2022
Editorial CommentNicolas Sayegh, Umang Swami
The Journal of Urology|August 30, 2021
Editorial CommentUmang Swami, Neeraj Agarwal
Cancer Treatment and Research Communications|August 22, 2020
Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancerUmang Swami, Neeraj Agarwal
Annals of Translational Medicine|July 19, 2021
Cancer immunotherapy: recent advances and challengesUmang Swami, Mohammed Milhem
The Lancet. Oncology|October 3, 2021
Drug development in metastatic prostate cancer: lessons from ACISUmang Swami, Neeraj Agarwal
Current Drug Targets|April 20, 2013
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxisUmang Swami, Sanjay Goel, Sridhar Mani
The Oncologist|March 31, 2019
The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial CarcinomaUmang Swami, Petros Grivas, Neeraj Agarwal
JCO Oncology Practice|September 2, 2021
Recent Advances in the Management of Metastatic Prostate CancerNicolas Sayegh, Umang Swami, Neeraj Agarwal
Expert Review of Anticancer Therapy|February 19, 2020
The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacyPedro Barata, Umang Swami, Neeraj Agarwal
Marine Drugs|August 12, 2015
Eribulin in Cancer TreatmentUmang Swami, Umang Shah, Sanjay Goel
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
The Journal of Urology|February 10, 2022
Editorial CommentNicolas Sayegh, Umang Swami
The Journal of Urology|August 30, 2021
Editorial CommentUmang Swami, Neeraj Agarwal
Cancer Treatment and Research Communications|August 22, 2020
Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancerUmang Swami, Neeraj Agarwal
Annals of Translational Medicine|July 19, 2021
Cancer immunotherapy: recent advances and challengesUmang Swami, Mohammed Milhem
The Lancet. Oncology|October 3, 2021
Drug development in metastatic prostate cancer: lessons from ACISUmang Swami, Neeraj Agarwal
Current Drug Targets|April 20, 2013
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxisUmang Swami, Sanjay Goel, Sridhar Mani
The Oncologist|March 31, 2019
The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial CarcinomaUmang Swami, Petros Grivas, Neeraj Agarwal
JCO Oncology Practice|September 2, 2021
Recent Advances in the Management of Metastatic Prostate CancerNicolas Sayegh, Umang Swami, Neeraj Agarwal
Expert Review of Anticancer Therapy|February 19, 2020
The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacyPedro Barata, Umang Swami, Neeraj Agarwal
Marine Drugs|August 12, 2015
Eribulin in Cancer TreatmentUmang Swami, Umang Shah, Sanjay Goel
Pageof 17